美国慢性肝病与肝硬化死亡率趋势:COVID-19大流行前后
本研究利用美国国家生命统计系统的临时数据,估计2017年第一季度至2020年第三季度慢性肝病与肝硬化相关死亡率的季度时间趋势。
要点
- COVID-19大流行期间慢性肝病与肝硬化患者并发症和死亡风险更高。
- 研究评估2017Q1至2020Q3美国慢性肝病与肝硬化相关死亡率季度趋势。
核心结论
- 研究估计了2017年第一季度至2020年第三季度美国慢性肝病与肝硬化相关死亡率的季度时间趋势。
研究设计与样本
- 基于美国国家生命统计系统临时数据发布的时序分析,覆盖2017年第一季度至2020年第三季度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic liver disease (CLD) and cirrhosis accounts for approximately 2 million deaths annually worldwide. CLD and cirrhosis-related mortality has increased steadily in the United States.1,2 With the global pandemic of coronavirus disease 2019 (COVID-19), patients with CLD and cirrhosis represent a vulnerable population at higher risk for complications and mortality.3,4 Although high mortality from COVID-19 among patients with CLD and cirrhosis have been reported,5 national trends in mortality related to CLD and cirrhosis before and during the COVID-19 pandemic have not been assessed. This study estimated the temporal quarterly trends in CLD and cirrhosis-related mortality in the United States from 2017 Q1 to 2020 Q3 using provisional data releases from the National Vital Statistics System.6,7.
引用
- Kim D, Bonham CA, Konyn P, et al. Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2021. PMID: 34256143. doi:10.1016/j.cgh.2021.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。